|
Ortiz-Fernandez P, Iniesta-Navalon C, Urbieta-Sanz E, Gascon-Canovas JJ. Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: "early therapeutic drug monitoring of adalimumab". Clin Rheumatol. 2025 Jan 18. doi: 10.1007/s10067-025-07307-0. Online ahead of print. PubMed PMID: 39826047.
AÑO: 2025; IF: 2.9
|
|
Iniesta-Navalon C, Saorin MR, Neira-Torrecillas JM, Rentero-Redondo L, Garcia-Masegosa I, Gil-Almela J, Urbieta-Sanz E. External Evaluation of Population Pharmacokinetic Models of Ustekinumab in Patients with Inflammatory Bowel Disease. Ther Drug Monit. 2025 Apr 3. doi: 10.1097/FTD.0000000000001329. Online ahead of print. PubMed PMID: 40178486.
AÑO: 2025; IF: 2.8
|
|
Iniesta-Navalón C., Saorín M.R., Neira-Torrecillas J.M., Rentero-Redondo L., Garcia-Masegosa I., Gil-Almela J., Urbieta-Sanz E. External Evaluation of Population Pharmacokinetic Models of Ustekinumab in Patients with Inflammatory Bowel Disease. Therapeutic Drug Monitoring. 2025. 10.1097/FTD.0000000000001329
AÑO: 2025; IF: 2.8
|
|
Iniesta Navalon C, Rios-Saorin M, Rentero-Redondo L, Nicolas-de Prado I, Gomez-Espin R, Urbieta Sanz E. Impact of ustekinumab exposure on clinical outcomes during induction in inflammatory bowel disease. Rev Esp Enferm Dig. 2024 Dec 4. doi: 10.17235/reed.2024.10521/2024. Online ahead of print. PubMed PMID: 39629805.
AÑO: 2024; IF: 2.7
|
|
Iniesta-Navalon C, Rios-Saorin M, Rentero-Redondo L, Anez-Castano R, Urbieta-Sanz E. Comparative evaluation of point of care assay with ELISA techniques for quantifying serum concentrations of ustekinumab in inflammatory bowel disease patients. Gastroenterol Hepatol. 2024 Oct 21:S0210-5705(24)00284-X. doi: 10.1016/j.gastrohep.2024.502277. Online ahead of print. English, Spanish. PubMed PMID: 39442691.
AÑO: 2024; IF: 2.2
|